Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Inclusion Criteria:

- Provide signed written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.

- Male or female, 18 years or older (at the time consent is obtained)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Part 1/dose escalation; Histologically or cytologically confirmed diagnosis of
Multiple Myeloma in a subject who fulfills all of the following: has undergone stem
cell transplant, or is considered transplant ineligible, has been pretreated with at
least the 3 following classes of anti-myeloma drugs: alkylators, proteasome inhibitors
and immunomodulators, has demonstrated progression on, or within 60 days of completion
of the last therapy.

Part 2 /MM cohort; Histologically or cytologically confirmed diagnosis of: Multiple Myeloma
in a subject who fulfills all of the following: has undergone stem cell transplant, or is
considered transplant ineligible, has been pretreated with at least the 3 following classes
of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has
demonstrated progression on, or within 60 days of completion of the last therapy, and has
measurable disease with at least one of the following: serum M-protein >=0.5 gram
(g)/decilitre (dL) (>=5 g/Litre (L)), urine M-protein >=200 milligram (mg)/24hour (h).

Serum free light chain (FLC) assay: Involved FLC level >=5 mg/dL (>=50 mg/L) and an
abnormal serum FLC ratio (<0.26 or >1.65) and biopsy proven plasmacytoma (should be
measured within 28 days of Screening Visit).

- Part 2/Other BCMA positive Hematologic Malignancies cohort: Subject with one of the
following lymphomas: Diffuse Large B-cell Lymphoma (DLBCL) or follicular lymphoma (FL)
that exhibits positive BCMA expression on tumor cells as determined by a central
laboratory using a validated Immunohistochemistry (IHC) assay. Eligible subjects with
BCMA positive malignancies must also fulfill the prior treatment requirements as
follows: DLBCL: at least 2 prior lines of systemic therapy containing at least one
line of chemo-immunotherapy with anti-CD20 antibody, and either has undergone stem
cell transplant or is considered transplant ineligible. FL: at least 2 prior lines of
systemic therapy.

- Subjects with a history of autologous stem cell transplant are eligible for study
participation provided the following eligibility criteria are met: transplant was >
100 days prior to study enrolment, no active infection; subject meets the remainder of
the eligibility criteria outlined in the study protocol.

- Adequate organ system functions as defined below Absolute neutrophil
count>=1.0x10^9/L, hemoglobin>=8.0 g/dL, platelet>=50x10^9/L, international normalized
ration (INR) <=1.5, Partial thromboplastin time <=1.5xupper limit of normal (ULN),
total bilirubin <=1.25xULN, alanine aminotransferase and aspartate
aminotransferase<=1.5 X ULN, serum creatinine or calculated creatinine
clearance<1.2XULN >=60 mL/min for Part 1;>=50 mL/minute (min) for Part 2 if data
supports loosening criteria, Albuminuria<=500 mg/24h, left ventricular ejection
fraction >=50%, Troponin<=1xULN, Calcium<=1.1xULN

- A female subject is eligible to participate if she is of: Non-childbearing potential
or women of childbearing potential must have a negative serum pregnancy test within 72
hours of first dose of study treatment and agree to use effective contraception during
the study and for 60 days following the last dose of study treatment.

- Men with a female partner of childbearing potential must have either had a prior
vasectomy or agree to use effective contraception from the time of first dose of study
until 60 days after the last dose of study treatment to allow for clearance of any
altered sperm

- All prior treatment-related toxicities (defined by National Cancer Institute- Common
Toxicity Criteria for Adverse Events, version 4) must be <=Grade 1 at the time of
enrollment except for alopecia, and grade 2 neuropathy.

Exclusion Criteria:

- Systemic anti-tumor therapy within 14 days, or plasmapheresis within 7 days prior to
the first dose of study drug

- Use of an investigational drug within 14 days or five half-lives, whichever is
shorter, preceding the first dose of study drug. Prior treatment with a monoclonal
antibody within 30 days of receiving the first dose of study drug.

- History of an allogeneic stem cell transplant. Subjects with a history of an
autologous stem cell transplant are NOT excluded if they meet inclusion criteria
related to history of autologous stem cell transplant.

- Presence of active renal condition (infection, requirement for dialysis or any other
condition that could affect subject's safety). Subjects with isolated proteinuria
resulting from MM are eligible, provided they fulfil the inclusion criteria related to
organ system function.

- Evidence of active mucosal or internal bleeding

- Any major surgery within the last four weeks.

- Any serious and/or unstable pre-existing medical, psychiatric disorder, or other
conditions (including lab abnormalities) that could interfere with subject's safety,
obtaining informed consent or compliance to the study procedures.

- Known active infection requiring antibiotic treatment

- Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated
respiratory, hepatic, renal or cardiac disease

- Subjects with previous or concurrent malignancies are allowed only if the second tumor
is not contributing to the subject's illness. The subject must not be receiving active
therapy, other than hormonal therapy for this disease and the disease must be
considered medically stable for at least 2 years.

- Evidence of cardiovascular risk including any of the following: QT interval
corrected>=470 millisecond, evidence of current clinically significant uncontrolled
arrhythmias, history of myocardial infarction, acute coronary syndromes (including
unstable angina), coronary angioplasty, or stenting or bypass grafting within six
months of Screening, Class III or IV heart failure as defined by the New York Heart
Association functional classification system, uncontrolled hypertension, subjects with
intra-cardiac defibrillators or permanent pacemakers, abnormal cardiac valve
morphology (>=grade 2) documented by echocardiogram (subjects with grade 1
abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects
with moderate valvular thickening should not be entered on study.

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to GSK2857916 or any of the components of the study treatment.

- Pregnant or lactating female.

- Known human immuno virus infection.

- Subjects with positive test for Hepatitis B surface (HBS-Ag) or Hepatitis B core
(HBc)antigen

- Subjects with positive test for hepatitis C (HCV) infection are excluded regardless of
viral load. If hepatitis C antibody test is positive, a confirmatory polymerase chain
reaction (PCR) or Recombinant immunoblot assay (RIBA) test should be performed. If the
PCR or RIBA test is negative, subject is eligible for this trial

- Current active liver or biliary disease (with the exception of Gilbert's syndrome or
asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease
per investigator's assessment).

- Current corneal disease or a history of corneal disease.